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ABSTRACT 
A simple, precise and economical, and rapid Spectrophotometric methods for the quantification of Linezolid in bulk material and in tablets. 
Further, this study is designed to validate the developed methods as per ICH guidelines. Material & methods: In Methods A and B, a stock 
standard solution was prepared by dissolving 10 mg of Linezolid in 100 mL of phosphate buffer pH 7.4 to obtain a concentration of 100 μg/mL. 
After suitable dilution, 10 μg/mL of  Linezolid was prepared and scanned in the UV-visible range 400 –200 nm;  In method A zero order 
spectrum Linezolid showed a maximum absorbance at 251 nm. while in Method B  area under curve (AUC) zero-order spectrum was recorded 
between 245 and 268 nm. For a linearity study, series of dilutions were prepared from stock solutions.  Results: In Method A and B, Linezolid 
followed linearity in the concentration range of 3 – 18 μg/mL with (r2 = 0.9978) (r2 = 0.9981). The accuracy of the method was checked by 
recovery experiment performed at three different levels i.e., 80%, 100% and 120%. The % recovery was found to be in the range 96.15% – 
99.32% for method A, while in method B range is 99.16 % - 100.20 %. The low values of % RSD are indicative of the accuracy and 
reproducibility of the method. The precision of the method was studied as an intra-day, inter-day variations and repeatability. The % R.S.D. 
value less than 2 indicate that the method was precise. Ruggedness of the proposed method was studied with the help of two analysts. The 
proposed method of pharmaceutical formulation the amounts of Linezolid estimated by both these methods (A and B) were found to be 96.25 ± 
0.44 and 99.48 ± 1.05, respectively. Conclusion: The developed methods are simple, precise, rugged, and economical. Both these methods can 
be used for routine analysis of Linezolid from its tablet formulation.  
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 Linezolid is a synthetic antibiotic, the first commertially 
available of the 1, 3-oxazolidinone antibiotic class, used for 
the treatment of infections caused by multi-resistant bacteria 
including streptococcus and methicillin-resistant 
Staphylococcus aureus (MRSA).[1] Chemical name of 
Linezolid (LIN) 1is N-{[(5S)-3-[3-fluoro-4-(morpholin-4-
yl)phenyl]-2-oxo- 1,3-oxazolidin-5-yl]methyl}acetamide. It 
has an empirical formula of C16H20FN3O4 and a molecular 
weight of 337.346 g/mol. [2] Linezolid is active after oral or 
intravenous administration. [3] It inhibits bacterial protein 
synthesis by actingat an early step and a site different from 
that of other AMAs. It binds to 23s fraction of the50s 
ribosome and interfere with formations of the ternary N-
formylmethionine-t- RNA-70sinitiation complex. Binding of 
linezolid distorts the t-RNA binding site overlapping both 
50sand 30s ribosomal subunits and stops protein synthesis 
before it starts. [4] Appropriate use of Linezolid is essential 
to minimize the risk of resistance development in Gram 
positive bacteria. The availability of both parenteral and oral 
formulations provides the opportunity to transfer 
appropriate patients to an oral formulation. [5] Linezolid is 
administered as intermittent intravenous dose of 600mg 
every 12 h, without loading dose. [6] 
 
Structure of Linezolid 
 Literature survey reveals that several analytical methods 
have been reported for the estimation of Linezolid by 
Spectroscopic methods such as UV/Vis, difference 
spectrophotometric method combination with other drugs 
[7] and Apart from above  the other methods are Chiral HPLC 
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Method[8], and HPTLC [9] methods were reported for this 
compound. 
 UV spectrophotometric method was reported for the 
quantitative determination of Linezolid in pharmaceutical 
dosage forms. The developed method was simple, precise, 
specific and accurate analysis proved that method is 
reproducible and selective for the analysis of Linezolid in 
bulk drug and tablet. 
EXPERIMENTAL WORK 
Instrument: 
A double beam UV-VIS spectrophotometer (UV-2450, 
Shimadzu, Japan) connected to computer loaded with spectra 
manager software UV Probe with 10 mm quartz cells was 
used. The spectra were obtained with the instrumental 
parameters as follows: Wavelength range: 200 – 400 nm; 
scan speed: Medium; sampling interval: 1.0 nm. 
Material and Methods: 
Active Pharmaceutical Ingredient (API) of Linezolid supplied 
by ALEMBIC Pharmaceutical 
Limited, Vadodara, India) As the tablet formulation was 
available in Indian market, LIDOMAX-600mg tablets were 
used as pharmaceutical formulation for further analysis. 
Solvent used for preparation of solution is phosphate buffer 
pH 6.4, phosphate buffer pH 7.4 and Methanol. 
Preparation of solvent:  
 Phosphate buffer pH 6.4 : Dissolve 1.79gm of disodium 
hydrogen phosphate, 1.36gm of potassium dihydrogen 
phosphate and 8.0 gm of sodium chloride in sufficient 
water to produce 1000ml. and adjust the pH, if 
necessary. 
 Phosphate buffer pH 7.4 : Dissolve 2.38 gm of disodium 
hydrogen phosphate, 0.19 gm of potassium dihydrogen 
phosphate and 8.0 gm of sodium chloride in sufficient 
water to produce 1000ml. and adjust the pH, if 
necessary.[10] 
Preparation of standard stock solution: 
A standard stock solution of Linezolid was prepared by 
dissolving accurately weighed 10mg of the drug in phosphate 
buffer pH 7.4 in 100ml volumetric flask, sonicate and to 
obtain the concentration of 100 µg/ml for method A and B .  
Methods: 
A. Zero order UV spectrophotometric method :  
 Determination of wavelength: 
1. Methanol: From the standard stock solution; 1 ml (100 
µg/ml) was diluted with 10 ml methanol to obtain the 
concentration of 10 µg/ml. and this solution was 
scanned in the UV-region 400 - 200nm. Linezolid 
showed λmax at 251nm (Fig.1) 
2. Phosphate buffer pH 6.4  : From the standard stock 
solution; 1 ml (100 µg/ml) was diluted with 10 ml 
Phosphate buffer pH  to obtain the concentration of 10 
µg/ml. and this solution was scanned in the UV-region 
400 - 200nm. Linezolid showed λmax at 251nm (Fig.2) 
3. Phosphate buffer pH 7.4: From the standard stock 
solution; 1 ml (100 µg/ml) was diluted with 10 ml 
solvent to obtain the concentration of 10 µg/ml. and 
this solution was scanned in the UV-region 400 - 
200nm. Linezolid showed λmax at 251nm (Fig.3) 
B. Area under curve UV spectrophotometric method: 
 Determination of wavelength : From the standard stock 
solution; 1 ml (100 µg/ml) was diluted with 10 ml Phosphate 
buffer pH 7.4  to obtain the concentration of 10 µg/ml. and 
this solution was scanned in the UV-region 400 - 200nm. 
Linezolid shows maximum absorbance at 251nm. And the 
AUC of zero order spectrum was recorded between 245 – 
268nm. (Fig.4)[11] 
Validation of The Method: 
1. Linearity: 
Different aliquots of linezolid in range 3 – 1.8 ml were 
transferred into series of 10 ml volumetric flasks and the 
volume was made up to the mark with water to get 
concentrations 3,6,9,12,15, and 18 μg/ml, for method A and 
method B.  
2. Accuracy (% Recovery): 
To the pre analyzed sample solutions, a known amount of 
standard stock solution was added at different levels i.e. 
80%, 100% and 120%. The solutions were reanalyzed by 
proposed method.[12] 
3. Precision: 
Precision of the method was studied as intraday and inter-
day variations. For method A and B Intra-day precision was 
determined by analyzing the 9,12 and 15 μg/ml of  Linezolid  
solutions for three times in the same day. Inter-day precision 
was determined by analyzing the 12 , 15 and 18 μg/ml of  
Linezolid solutions daily for three days over the period of 
week.[13] 
4. LOD and LOQ (Sensitivity): 
The sensitivity of measurements of Linezolid by the use of 
the proposed method was estimated in terms of the Limit of 
Quantification (LOQ) and Limit of Detection (LOD). The LOQ 
and LOD were calculated using equation LOD = 3.3 x N/B and 
LOQ = 10 x N/B, where, ‘N’ is standard deviation of the peak 
areas of the drugs (n =3), taken as a measure of noise, and ‘B’ 
is the slope of the corresponding calibration curve.[14] 
5. Repeatability:  
Repeatability was determined by analyzing  5 μg/ml foe 
method A, while in method B 8 µg/ml concentration of 
Linezolid solution for six times. 
6. Ruggedness: 
Ruggedness of the proposed method is determined for 12 
μg/ml concentration of by analysis of dilution from 
homogenous slot by two analysts using same operational and 
environmental conditions. For method A and B. 
7. Analysis Of Bulk Material : 
From the standard stock solution of Linezolid, an 
appropriate volume 9 ml was diluted to 10 ml mark to obtain  
9 µg/ml for method A , while in method B volume 12ml was 
diluted to 10 ml mark to obtain 12µg/ml the resulting 
solution was scanned in UV-spectrophotometer between 
200-400 nm. The spectrum was recorded at 251nm.[15] 
8. Analysis Of Tablet Formulation: 
For the analysis of commercial formulation, LIDOMAX-600 
twenty tablets were weight;    average 5weight was 
determined and crushed into fine powder.  A quantity of 
drug equivalent to 10 mg of Linezolid was transferred into  
100 mL of volumetric flaks containing 50 mL of Phosphate 
buffer pH7.4, shaken manually for  25 min and volume was 
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made up to the mark with same solvent and filtered through  
Whatmann  filter paper no 41. An  appropriate  volume 9 mL  
was  diluted  to   10  mL  mark  to  obtain  9µg/mL for method 
A, while in method B volume 12 ml was diluted to 10 ml 
mark to obtain 12µg/ml concentration. and scanned in UV-
spectrophotometer between 200-400nm. the analysis 
reported for six times.[16] 
 
RESULT AND DISSCUSSION 
Determination of λ
max
 in different solvents or buffers: 
1. Trial : Methanol   
 
Figure 1 Linezolid scan in Methanol showing λmax 257nm. 
 
2. Trial  : Phosphate buffer pH 6.4 
 






3. Trial : Phosphate buffer pH 7.4 
 
Figure 3 Linezolid scan in phosphate buffer pH 7.4 for 




Figure 4 AUC Zero Order Spectrum of Linezolid showing 
absorbance maximum at 245-268 nm 
METHOD VALIDATION: 
Phosphate buffer pH 7.4 was selected for Method Validation 
of Linezolid by Zero order derivative and AUC Zero order 
Derivative. 
1. Linearity: 
The linear regression data for the calibration curves showed 
good linear relationship over the concentration range 3-
18μg/ml for Linezolid (Fig.5,6). Linear regression equation 
was found to be Y=0.0543x + 0.0243 (r2 = 0.9978) Y= 
0.0543x + 0.0205 (r2 = 0.9981) for method A and B .The 
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Table 1:  Linearity studies of Linezolid 








Mean ± SD 
0 0 0 0 
3 0.198 3 0.2043   ±  0.0012 
6 0.357 6 0.3379   ±  0.0056 
9 0.595 9 0.5299   ±  0.0039 
12 0.674 12 0.668     ±  0.0089 
15 0.846 15 0.8357   ±  0.0021 
18 0.984 18 0.9901   ±  0.0060 
 
 
Figure 5 Linearity curve of Linezolid by Zero order 
derivatives 
 
Figure 6 Linearity curve of Linezolid by AUC Zero order 
derivatives                
2. Accuracy:  
The solutions were reanalyzed by proposed method; results 
of recovery studies are reported in Table 2 , In method A, the 
mean % recovery was found to be in the range of 96.15 – 
99.32 % , while in method B, it was found to be in the range 
of 99.16 – 100.20 %,  for all three methods with %R.S.D.>2 
indicate that the methods were precise. 
Table 2: Accuracy studies of Linezolid 
% 
value 








80% 96.15  ±  0.69 0.72 99.16 ±  0.71 0.72 
100% 99.05 ± 0.43 0.44 99.26 ± 1.22 1.24 
120% 99.32 ± 0.53 0.56 100.20 ± 0.60 0.60 
*(n=3)
 
3. PRECISION:  
The precision of the developed method was expressed in terms of % relative standard deviation (% RSD). These result shows 
reproducibility of the assay. The % R.S.D. values found to be less than 2, so that indicate this method precise for the 
determination of both the drugs in formulation (Table 3) 




Intra-day precision Inter-day precision 
Amount found* % RSD Amount found* % RSD 
A 
9 8.94 0.57 8.91 0.70 
12 11.97 0.84 11.96 0.93 
15 14.94 0.82 14.86 0.43 
B 
12 11.99 0.62 11.89 0.77 
15 14.91 0.69 14.88 0.49 
18 17.84 0.70 17.87 0.77 
 
4. SENSITIVITY:  
The linearity equation was found to be Y=0.1353x – 0.0558 
(r2 = 0.9982). The LOQ and LOD for Linezolid were found to 
be 0.28 μg and 0.85 μg, for method A. while in method B 
linearity equation was found to be y = 0.1382x – 0.0812 (r²= 
0.9962). The LOQ and LOD for Linezolid were found to be 
0.48 μg and 1.47 μg   respectively (Table 4) 
 
Table 4: Sensitivity studies of Linezolid 
Methods Linear regression equation LOD (µg/ml) LOQ(µg/ml) 
            A y = 0.1353x – 0.0558 (r²= 0.9982) 0.28 0.85 
            B y = 0.1382x – 0.0812 (r²= 0.9962) 0.48 1.47 
 
y = 0.0543x + 0.0243 
















y = 0.0543x + 0.0205 
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5. REPEATABILITY:  
Repeatability was determined for selected concentrations of Linezolid solution for six times and the % amount determined with 
% RSD less than 2 for all the two methods. The results are expressed in Table 5. 
Table 5: Repeatability studies of Linezolid 
Methods Amount taken (µg/ml) Amount found* % Amount found*± SD % RSD 
A 5 4.91 98.35 ±1.54 1.57 
B 8 7.94 99.31 ± 1.30 1.32 
 
6. Ruggedness 
Peak area was measured for same concentration solutions, six times. The results are in the acceptable range for the drugs. The 
results are given in Table *. The result showed that the % R.S.D. was less than 2 %.( Table 6) 




Analyst I Analyst II 
% Amount found*± SD % RSD % Amount found*± SD % RSD 
       A 12 99.24 ±  1.42 1.43 99.32 ± 0.92 0.94 
       B 12 99.45  ±  1.37 1.38 99.01  ±  1.22 1.23 
 
7. Determination of Linezolid in bulk:  
The concentrations of the drug were calculated from linear regression equations. The % amount found was between % to % 
(Table 7). 
Table 7: Analysis of Linezolid in bulk 
Methods Amount taken (µg/ml) Amount found* % Amount found*± SD % RSD 
A 9 8.72 96.98  ±  0.31 0.32 
B 12 11.98 99.88  ±  0.93 0.93 
 
8. Analysis of Linezolid in tablet formulation:  
The spectrum was recorded at 251nm. The concentrations of the drug were calculated from linear regression equation. The % 
amount was found between % to % (Table 8).  
Table 8: Analysis of Linezolid in tablet formulation 
Methods Amount taken (µg/ml) Amount found* % Amount found*± SD % RSD 
A 9 8.66 96.25 ± 0.44 0.45 
B 12 11.93 99.48± 1.05 1.06 
 
CONCLUSION 
The spectrophotometric both developed methods are economical, simple, accurate, precise and rugged, and can be used for the 
usual study of Linezolid from its pharmaceutical formulations. The methods are developed for quantification on Linezolid in 
tablets. It is also used in routine quality control of the formulations containing Linezolid.  
Parameter Method A Method B 
Beer’s-Lamberts’s range(µg/ml) 3 - 18µg/ml 3 - 18µg/ml 
Regression equation (y=mx + c) 0.0543x + 0.0243 0.0543x + 0.0205 
Correlation coefficient(r2) 0.9978 0.9981 
Slope(m) 0.0543 0.0543 
Intercept(C) 0.0243 0.0205 
Repeatability(n=6) 
Ruggedness : Analyst I 
                      Analyst II 
98.35 ± 1.54 
99.24 ± 1.42 
99.32 ± 0.92 
99.31 ± 1.30 
99.45 ± 1.37 
99.01 ± 1.22 
LOD(µg/ml) 0.28 0.85 
LOQ(µg/ml) 0.48 1.47 
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